Literature DB >> 16949907

Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.

Mehsati Herawi1, Angelo M De Marzo, Glen Kristiansen, Jonathan I Epstein.   

Abstract

Numerous studies have claimed that CDX2 is relatively specific and sensitive in establishing a gastrointestinal origin in metastatic tumors of unknown origin. We have recently seen 2 cases of prostatic adenocarcinoma (PCa) on needle biopsies with diffuse strong nuclear staining for CDX2 sent for consultation. One case was a prostatic duct adenocarcinoma in a man with a prostate-specific antigen (PSA) value of 327 ng/mL, and the other was a PCa with a Gleason score (GS) of 4 + 4 = 8 in a man with a PSA value of 15 ng/mL. An adenocarcinoma with GS 3 + 3 = 6 from the contralateral side did not express CDX2. Because documented examples of this phenomenon are rare, we investigated the immunoexpression of CDX2, using tissue microarrays (TMAs). Three slides of TMAs were used to stain 708 tissue samples (0.6 mm in diameter) containing either benign or malignant prostate tissue, as well as control tissues from various anatomical sites including colon. In total, 195 samples of primary PCa with GS of 6 (n = 41), 7 (n = 21), and 8 (n = 8); 195 samples of benign prostate tissue; and 185 samples of metastatic PCa were studied. Of 70 radical prostatectomy specimens examined for PCa in TMAs, 4 (5.7%) were positive for CDX2, showing Gleason score of 6 (n = 3) and Gleason score of 7 (n = 1). Focal moderate positive staining was seen in benign prostate tissue in 7 (11.7%) of 60 radical prostatectomy specimens. None of the metastatic PCa expressed CDX2. CDX2 may uncommonly be focally expressed in benign prostatic glands. Staining in PCa is less common and appears independent of GS and is usually patchy and focal and of lesser intensity than in colonic tissue. However, rarely strong and diffuse staining may be seen. Positive CDX2 staining in high-grade prostate cancer (ductal, cribriform, and solid) may be confused with secondary carcinoma of colonic origin. Routine histopathology, positive PSA immunostaining, and clinical findings can help confirm the correct diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16949907     DOI: 10.1016/j.humpath.2006.06.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  CDX2 as a marker for intestinal differentiation: Its utility and limitations.

Authors:  Reda S Saad; Zeina Ghorab; Mahmoud A Khalifa; Mei Xu
Journal:  World J Gastrointest Surg       Date:  2011-11-27

2.  Calcium intake and prostate cancer among African Americans: effect modification by vitamin D receptor calcium absorption genotype.

Authors:  Glovioell W Rowland; Gary G Schwartz; Esther M John; Sue Ann Ingles
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

Review 3.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

4.  Prostate adenocarcinoma with a rectal metastasis.

Authors:  Nwabundo Nwankwo; Aibek E Mirrakhimov; Teresita Zdunek; Nora Bucher
Journal:  BMJ Case Rep       Date:  2013-04-30

5.  CDX-2 expression in malignant germ cell tumors of the testes, intratubular germ cell neoplasia, and normal seminiferous tubules.

Authors:  Michael J Lee; Adam P Vogt; Wayland Hsiao; Adeboye O Osunkoya
Journal:  Tumour Biol       Date:  2012-08-16

6.  Expression of CDX2 in metastatic prostate cancer.

Authors:  C Guerrieri; Z Jobbagy; R Hudacko
Journal:  Pathologica       Date:  2019-09

7.  Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Authors:  Amanda H Seipel; Hemamali Samaratunga; Brett Delahunt; Fredrik Wiklund; Peter Wiklund; Johan Lindberg; Henrik Grönberg; Lars Egevad
Journal:  Virchows Arch       Date:  2014-07-25       Impact factor: 4.064

8.  Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach.

Authors:  Brian T Kawasaki; Elaine M Hurt; Madhuri Kalathur; Maria Ana Duhagon; John A Milner; Young S Kim; William L Farrar
Journal:  Prostate       Date:  2009-06-01       Impact factor: 4.104

9.  Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures.

Authors:  Xiao-Tong Wang; Wei-Yuan Wei; Fan-Biao Kong; Chao Lian; Wen Luo; Qiang Xiao; Yu-Bo Xie
Journal:  J Exp Clin Cancer Res       Date:  2012-11-26

10.  Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients.

Authors:  S C C Wong; S S M Ng; M T Cheung; L Y Luk; C M L Chan; A H K Cheung; V H M Lee; P B S Lai; B B Y Ma; E P Hui; M Y Y Lam; T C C Au; A T C Chan
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.